Brief: Candel Therapeutics Q2 Basic EPS USD -0.33
10/08/2023 13:11
Aug 10 (Reuters) - Candel Therapeutics Q2 operating expenses USD 9.579 million. * Q2 income from operations USD -9.579 million * Q2 net income USD -9.614 million * Q2 basic EPS USD -0.33
Recent news on Candel Therapeutics
See all newsBrief: Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Candel Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Candel Therapeutics Reports Second Quarter 2026 Financial Results And Recent Corporate Highlights
Candel Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview
Brief: Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)